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Germline PHOX2B Mutation in Hereditary
Neuroblastoma
To the Editor:
We read with interest the study by Trochet and col-
leagues (2004), published in the April 2004 issue of The
American Journal of Human Genetics, that described
germline mutations of the paired-like homeobox 2B gene
(PHOX2B [MIM 603851]) in neuroblastoma (MIM
256700). We have also considered PHOX2B as a can-
didate gene for predisposition to neuroblastoma, and we
now report on a germline PHOX2B mutation in a ped-
igree with neuroblastoma. However, we also show that
there is no evidence for mutation of this gene in eight
other pedigrees with neuroblastoma screened to date.
We think these data establish PHOX2B as the ﬁrst bona
ﬁde gene that can predispose to neuroblastoma when
mutated in the germline, and the ﬁndings further em-
phasize the complex genetics of this important pediatric
malignancy.
We previously demonstrated linkage of hereditary
neuroblastoma to 16p12-13 by use of a genomewide
screening strategy (Maris et al. 2002). Positional cloning
of a putative 16p12-13 hereditary neuroblastoma-pre-
disposition gene (HNB1) is ongoing, but the critical ge-
nomic region for this gene remains large. We had pre-
viously considered and excluded other genes known to
be mutated in Hirschsprung disease (MIM 142623) and/
or in congenital central hypoventilation syndrome
(CCHS [MIM 209880]) as candidates for HNB1, be-
cause these disorders can occur coincident with both
sporadic and hereditary neuroblastoma (Maris et al.
2002). Because of the recent reports that the vast ma-
jority of patients with CCHS harbor PHOX2B muta-
tions, including two patients also affected with neuro-
blastoma (Amiel et al. 2003; Weese-Mayer et al. 2003),
we initiated a screen for germline mutations in this gene
in our series of pedigrees with neuroblastoma.
Oligonucleotide primer pairs ﬂanking the coding
regions of exons 1, 2, and 3 of PHOX2B were designed
by use of the program Primer 3.0; these primer pairs
were used for PCR ampliﬁcation and bidirectional se-
quencing of puriﬁed PCR products (primer sequences
available on request). We screened germline DNA from
the proband and an unaffected family member for each
of the seven families that showed cosegregation of a 16p
haplotype with disease, as well as for two pedigrees that
consisted of cousins with neuroblastoma with no coseg-
regation of 16p marker haplotypes (see Maris et al.
[2002] for details of pedigrees). We also sequenced 109
control DNA samples from the Coriell SNP500 Cancer
Panel (Coriell Cell Repositories). All sequence aberra-
tions were conﬁrmed by repeat sequencing after cloning
of puriﬁed PCR products (TOPO TA Cloning Kit [In-
vitrogen]), and DNA samples from the remaining avail-
able members of the pedigree were also screened for the
variant. The Children’s Hospital of Philadelphia insti-
tutional review board approved this work.
A heterozygous single-base deletion (676delG) was
discovered in a complex pedigree with neuroblastoma
(ﬁg. 1) (see dbSNP Home Page). This family has seven
members in three generations affected with neuro-
blastoma, and two of these individuals were also shown
to have Hirschsprung disease. The proband was affected
with neuroblastoma, Hirschsprung disease, and neuro-
ﬁbromatosis type 1 (MIM 162200). The putative non-
sense mutation 676delG segregated with neuroblastoma
through all three generations, and the frameshift was
predicted to produce a slightly truncated protein that
would no longer code for the second polyalanine tract.
This family had previously been shown to cosegregate
a 16p12-13 haplotype with neuroblastoma, and the pro-
band was also shown to have an inactivating mutation
in NF1 (3775delT) that was not present in either of her
parents (Maris et al. 2002). Tumor material was avail-
able only for patient 1-001, and the tumor exon 3 se-
quence remained heterozygous for the 676delG muta-
tion. In addition, loss-of-heterozygosity studies using
microsatellite markers (D4S2912, D4S1587, D4S405,
D4S2971, and D4S428) that are closely linked to the
PHOX2B locus showed no evidence for allelic deletion.
The only other sequence variant discovered in the re-
maining eight pedigrees was a putative SNP (C552T) in
pedigree 12 that is not predicted to affect the resultant
protein sequence (S184S) (see dbSNP Home Page). This
Figure 1 Germline PHOX2B mutation in a pedigree segregating neuroblastoma and Hirschsprung disease. A, Family 1 pedigree structure.
DNA samples from this family with neuroblastoma were available only for patients with a PHOX2B result shown (wt p wild type; 676delG
p heterozygous mutation segregating through three generations). Patients 1-001 and 1-010 also had Hirschsprung disease, and patient 1-001
was affected with neuroﬁbromatosis type 1. B, Genomic organization of PHOX2B and schematic representation of the PHOX2B protein. The
homeobox domain and the 9– and 20–amino-acid polyalanine repeats are shown for both schemas (pink, yellow, and dark red boxes, respectively).
The location of the 676delG mutation is shown (arrow). C, DNA sequence electropherograms from exon 3 of the PHOX2B gene, showing a
heterozygous single-base deletion at G676 (arrow) that segregates through all three generations but does not appear in a representative unaffected
family member.
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sequence variant was present in the proband but was
not detected in the patient’s affected father (no maternal
DNA sample was available). It is important to note that
neither sequence variant was identiﬁed in the bidirec-
tional sequencing of 218 alleles from the control sample
set. This strongly suggests that the 676delG sequence
variant that segregates with the disease phenotype is a
true mutation. The C552T sequence variant, which does
not segregate with the disease, is more likely a very rare
polymorphism, but we cannot formally exclude the pos-
sibility that there might be a functional effect of this
presumably neutral polymorphism.
Accumulated data strongly implicate PHOX2B as an
essential regulator of normal autonomic nervous system
development (Pattyn et al. 1999; Brunet and Pattyn
2002). The discovery of polyalanine-expansion muta-
tions in the majority of patients with CCHS clearly de-
ﬁnes a role for this gene in human disease (Amiel et al.
2003; Weese-Mayer et al. 2003), and there appears to
be a correlation between the severity of the respiratory
symptoms and the length of polyalanine expansion
(Weese-Mayer et al. 2003; Matera et al. 2004). Neuro-
blastoma represents perhaps the most aberrant pheno-
type that results from abnormal adrenergic tissue de-
velopment. The rare but well-described synchronous
appearance of neuroblastoma with other disorders of
the autonomic nervous system has suggested a common
genetic etiology often referred to as a “neurocristopa-
thy” (Gaisie et al. 1979; Nemecek et al. 2003). Although
other genes implicated in Hirschsprung disease and/or
CCHS have not been excluded as hereditary neuro-
blastoma-predisposition genes (Maris et al. 2002; Perri
et al. 2002), our data further establish PHOX2B as an
important gene involved in the initiation of neuro-
blastoma tumorigenesis. However, the fact that the ma-
jority of pedigrees studied here do not show PHOX2B
mutations clearly implicates locus heterogeneity for he-
reditary predisposition to neuroblastoma. Assuming that
our inferences of linkage to 16p are correct, and in light
of the observation of two germline mutations in the pro-
band of the family presented here, we suggest that an
oligogenic mechanism for neuroblastoma initiation
should be considered, as has been shown for other dis-
eases of neural crest–derived tissues (Gabriel et al. 2002).
It is not yet clear if the PHOX2B mutations discovered
in patients with hereditary or sporadic neuroblastoma re-
sult in gain or loss of protein function. The hypothesis
that PHOX2B functions as a tumor suppressor is sup-
ported by the potential predicted consequence of the ﬁve
mutations described, to date, in patients with neuro-
blastoma. Weese-Mayer and colleagues discovered a non-
sense mutation that predicts a signiﬁcantly truncated pro-
tein that would miss most of exon 3, including all of the
20-alanine repeat motif (Weese-Mayer et al. 2003). The
frameshift mutation described here is similar to that re-
ported by Amiel and colleagues (2003) in a patient who
also had CCHS, Hirschsprung disease, and neuro-
blastoma, and, in both cases, the changes in reading
frame are predicted to abolish the polyalanine tract. Tro-
chet and colleagues (2004) discovered two missense mu-
tations, both of which map to a conserved portion of the
homeodomain and thus may interfere with DNAbinding.
On the other hand, 4p12 is not a known site of frequent
allelic deletion in neuroblastoma (Maris and Matthay
1999), and, to date, biallelic inactivation of PHOX2B
has not been demonstrated, although far too few cases
have been examined to assert this with conﬁdence.
Taken together, these data suggest that PHOX2B mu-
tations are involved in the initiation of neuroblastoma
tumorigenesis, especially in patients with associated dis-
orders of the autonomic nervous system. Our data also
indicate that germline mutational events in this gene are
not involved in the majority of hereditary neuroblastoma
cases and that alternative genetic events may predispose
to tumorigenesis. Examination of additional patients will
facilitate the deﬁnition of PHOX2B mutation frequency
in the genetic and (apparently) sporadic forms of neuro-
blastoma and will help to clarify the role of PHOX2B
mutations in tumor initiation and progression.
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Comparative Frequency of Fragile-X (FMR1) and
Creatine Transporter (SLC6A8) Mutations in X-Linked
Mental Retardation
To the Editor:
The study by Rosenberg et al. (2004), in the July 2004
issue of The American Journal of Human Genetics, and
the previous work by Dr. Salomons’s laboratory on the
implications of the creatine transporter gene, SLC6A8,
for X-linked mental retardation (XLMR) are very im-
portant contributions to the ﬁeld (Salomons et al. 2001;
Rosenberg et al. 2004). I wish, however, to qualify the
concluding sentences in the abstract and the discussion
section of the study by Rosenberg et al. (2004), which
may lead readers to overestimate the incidence of muta-
tions in the creatine transporter gene inmental retardation
(MR). The authors write in the abstract that the “fre-
quency of SLC6A8 mutations in XLMR is close to that
of CGG expansions in FMR1” (Rosenberg et al. 2004,
p. 97). This is certainly incorrect. Rosenberg et al. (2004)
found a 2.2% prevalence of SLC6A8 mutations in fam-
ilies with proven or possible XLMR (the latter are families
with at least two males affected by MR and compatible
with X-linked inheritance). On the other hand, the FMR1
expansion mutation associated with fragile-X syndrome
is found in ∼2%–3% of males with MR who were not
selected for family history (these ﬁgures are based on co-
horts with little clinical preselection apart from the ex-
clusion of clearly chromosomal or syndromic forms of
MR) (see de Vries et al. 1997; Hecimovic et al. 2002;
Pandey et al. 2002; Grønskov et al. 2004; Biancalana et
al., in press). In fact, when selection is based on possible
X-linked inheritance, the proportion of individuals with
fragile-X syndrome is much higher. For instance, in the
study by Fishburn et al. (1983), fragile-X syndrome ac-
counted for MR in 12 of 45 male sib pairs with “non-
speciﬁc” MR, a proportion (27%) that is thus 110 times
higher than the reported incidence of SLC6A8 mutations
in a cohort containing sib pairs such as these as well as
families with even more obvious XLMR. In fact, we have
proposed recently that, unless there are clear hotspots of
mutations and/or a very large mutation target size (such
as for Duchenne muscular dystrophy, Rett syndrome, and
hemophilia A), the population incidence of X-linked dis-
eases implicating genes of average size that lead to highly
decreased reproductive ﬁtness is 10–20 times lower than
the incidence of fragile-X syndrome (1/50,000–1/100,000
for most X-linked diseases, compared with 1/∼5,000
males for the fragile-X syndrome) (Chelly and Mandel
2001). Thus, one expects that the contribution to XLMR
of an average gene that does not present mutation hot-
spots would be 10–20 times lower than that of FMR1.
